Pharmacodynamics of telithromycin In vitro against respiratory tract pathogens.
about
Pharmacodynamic profile of telithromycin against macrolide- and fluoroquinolone-resistant Streptococcus pneumoniae in a neutropenic mouse thigh modelCEM-101 activity against Gram-positive organisms.Telithromycin: an oral ketolide for respiratory infections.Ketolides in the treatment of respiratory infections.Postantibiotic effect of disinfection treatment by photolysis of hydrogen peroxide.Dead bugs don't mutate: susceptibility issues in the emergence of bacterial resistance.In vitro anti-listerial activities of crude n-hexane and aqueous extracts of Garcinia kola (heckel) seeds.Biocidal effects of stem bark extract of Chrysophyllum albidium G. Don on vancomycin-resistant Staphylococcus aureus.Telithromycin in the treatment of acute bacterial sinusitis, acute exacerbations of chronic bronchitis, and community-acquired pneumoniaPharmacodynamic functions: a multiparameter approach to the design of antibiotic treatment regimens.Postantibiotic effects of ABT-773 and amoxicillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae.Ketolide antimicrobial activity persists after disruption of interactions with domain II of 23S rRNA.Pharmacodynamic activity of telithromycin at simulated clinically achievable free-drug concentrations in serum and epithelial lining fluid against efflux (mefE)-producing macrolide-resistant Streptococcus pneumoniae for which telithromycin MICs varyStem bark extract and fraction of Persea americana (Mill.) exhibits bactericidal activities against strains of bacillus cereus associated with food poisoning.In vitro antilisterial properties of crude methanol extracts of Garcinia kola (Heckel) seeds.
P2860
Q33555366-C1830B9C-22B4-4D93-AA8F-E0546C3946AFQ34100146-5F8B0550-ECCF-4C6D-926B-CA21ACADBD35Q34401542-E265D67D-EECE-4BFA-A81A-FBDC4FF75BA1Q34544732-CCFF7A88-2E92-47CB-8E37-E93B89130C17Q35007552-5ACE61CB-9E8B-4A1C-B542-F03418674878Q35047705-9F45929D-FD48-4876-8E04-84B1C7F4DC98Q35536073-7B28A214-6CF3-4310-BA9B-ED08E7D72AB7Q35966573-20AA337D-A6FE-4D86-BFA4-412469858E2AQ37116814-6C38B49C-4E7E-4783-BF88-DDE011B0BA44Q37568933-F0C200EA-24C9-4127-A965-CADD926FF3D1Q39479282-73091B1D-776F-495F-BCE1-ABE7820166A4Q40165104-D842A955-5CC6-4F53-AFEE-6FEF2597B273Q42252396-5B40314B-DDDD-44A5-B025-876761BCBBCBQ52656337-A031A7B2-D0AD-4A9E-A180-546F15B4A8EBQ55031628-1AA1359D-E78B-4912-825C-648E4386F197
P2860
Pharmacodynamics of telithromycin In vitro against respiratory tract pathogens.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Pharmacodynamics of telithromycin In vitro against respiratory tract pathogens.
@ast
Pharmacodynamics of telithromycin In vitro against respiratory tract pathogens.
@en
type
label
Pharmacodynamics of telithromycin In vitro against respiratory tract pathogens.
@ast
Pharmacodynamics of telithromycin In vitro against respiratory tract pathogens.
@en
prefLabel
Pharmacodynamics of telithromycin In vitro against respiratory tract pathogens.
@ast
Pharmacodynamics of telithromycin In vitro against respiratory tract pathogens.
@en
P2093
P2860
P1476
Pharmacodynamics of telithromycin In vitro against respiratory tract pathogens.
@en
P2093
P2860
P356
10.1128/AAC.45.1.23-29.2001
P407
P577
2001-01-01T00:00:00Z